Glimepiride
Glimefine contains Glimepiride (sulfonylureas class) primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin. Therapy is effective in controlling blood glucose without deleterious changes in the plasma lipoprotein profiles of patients treated for Type 2 diabetes. GLIMEFINE (glimepiride) is indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
GLIMEFINE is also indicated for use in combination with insulin to lower blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent alone
Glimepiride 1mg / 2mg Tablet.